Warfarin IWPC Model: Maintenance dose estimation. Factors like Amiodarone and Genetics (CYP2C9/VKORC1) significantly alter VKA metabolism.
Ancestry / Race
Genomic Integration
Estimated Maintenance Dose
— mg/day
Enter patient clinical and/or genetic data to calculate.
Guidelines & Evidence
Clinical Details
Section 1
When to Use
When to Use
Estimating the stable maintenance dose of Warfarin in patients starting anticoagulation.
Integrating genetic (CYP2C9, VKORC1) and clinical (Age, Weight, Amiodarone) data to reduce time-to-INR-target.
Reducing the risk of early supratherapeutic INR and bleeding.
Patient Population
Adult patients requiring Vitamin K Antagonist (VKA) therapy for VTE, AF, or Valve replacement.
Section 2
Formula & Logic
Genetic Modifiers
Gene
Genetic Influence on Warfarin
VKORC1
Target of warfarin. G variant requires higher dose; A variant requires lower dose.
CYP2C9
Liver enzyme for metabolism. *2 and *3 variants lead to slow metabolism and require lower doses.
Clinical Modifiers
Age: Dose requirements decrease with age (~0.4 mg/day per decade).
Race: African Americans often require higher doses; Asians often lower.
Amiodarone: Potent inhibitor; usually requires 25-50% dose reduction.
Section 3
Pearls/Pitfalls
Genomic Advantage
While traditional "Trial and Error" dosing works, genomic-guided dosing reduces the hazard of early over-anticoagulation, particularly in patients with VKORC1 A/A or CYP2C9 *3/*3 genotypes who may be effectively anticoagulated on as little as 0.5 mg/day.
Section 4
Evidence Appraisal
Primary Score
Estimation of the warfarin dose with clinical and pharmacogenetic data.
International Warfarin Pharmacogenetics Consortium (IWPC) • New England Journal of Medicine. 2009;360(8):753-64.